IP Library Granted Patent US 10,815,237
Granted Patent B2
US 10,815,237 · App. 16/099,047 · Granted Oct 27, 2020

Antimicrobials and methods of making and using same

Inventors: Erin M. Duffy (Deep River, CT); Ashoke Bhattacharjee (Cheshire, CT); Zoltan F. Kanyo (North Haven, CT); Joseph A. Ippolito (Guilford, CT)
Assignee: BIOVERSYS AG
C07D487/04A61P31/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,815,237
App. No.
16/099,047
Granted
Oct 27, 2020
Kind
B2
Abstract

The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals. In some embodiments, the present disclosure provides a compound of Formula (I) or a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer.

Claims (43)

1. A compound of Formula (I):

or a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer, wherein:

R 1 is selected from H and halo;

R 2 is selected from H, halo, C 1-6 alkyl, C 1-4 haloalkyl, and OR a1 ;

R 3 is selected from H, C 1-6 alkyl, and C 1-4 haloalkyl;

W is selected from N and CR 4 ;

R 4 is selected from H, halo, OR a2 , SR a2 , 5-6 membered heterocycloalkyl, C 1-6 alkyl, and C 2-6 alkenyl, wherein the C 1-6 alkyl is optionally substituted with a substituent selected from OR a2 ;

R 5 is selected from H, halo, C 1-6 alkyl, and C 2-6 alkenyl, wherein the C 1-6 alkyl is optionally substituted with a substituent selected from OR a2 ;

R 6 is selected from H, C 1-6 alkyl, and C 2-6 alkenyl, wherein said C 1-6 alkyl is optionally substituted with OR a3 ;

R 7 is selected from H and C 1-6 alkyl; or

R 6 and R 7 together with the carbon atoms to which they are attached and the nitrogen atom connecting said two carbon atoms form a ring of formula:

R 8 is selected from H, C 1-6 alkyl, and C 1-4 haloalkyl;

X is selected from 0 and NR N ;

R N is selected from H and C 1-4 alkyl;

R A is H;

R B is H; or

R A and R B together with the nitrogen atom to which they are attached form a 5- to 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms selected from N, O and S, wherein said 5- to 6-membered heterocycloalkyl is optionally substituted with halo;

R 9 is selected from C 1-6 alkyl, C 2-6 alkenyl, C 3-5 cycloalkyl, wherein said C 1-6 alkyl is optionally substituted with a substituent selected from OR a3 and SR a3 ;

R 10 is selected from H, C 2-4 alkenyl, C 1-4 haloalkyl and C 1-4 alkyl optionally substituted with a substituent selected from amino, C 1-4 alkoxy, C 3-5 cycloalkyl, and 3- to 6-membered heterocycloalkyl;

R 11 is H or C 1-3 alkyl, wherein the C 1-3 alkyl is optionally substituted with OH;

each R a1 , R a2 , and R a3 is independently selected from H, C 1-6 alkyl and C 1-4 haloalkyl.

2. A compound according to claim 1 , wherein

R 9 is selected from C 1-6 alkyl, C 3-5 cycloalkyl, wherein said C 1-6 alkyl is optionally substituted with a substituent selected from OR a3 and SR a3 ; and

R 11 is H.

3. The compound of claim 1 , wherein R 1 is selected from H and fluoro.

4. The compound of claim 1 , wherein R 2 is selected from H, halo, C 1-4 haloalkyl, and C 1-4 haloalkoxy.

5. The compound of claim 1 , wherein R 2 is selected from H, chloro, trifluoromethyl, and trifluoromethoxy.

6. The compound of claim 1 , wherein R 3 is selected from H, and C 1-4 haloalkyl.

7. The compound of claim 1 , wherein R 3 is selected from H, and trifluoromethyl.

8. The compound of claim 1 , wherein W is N.

9. The compound of claim 1 , wherein W is CR 4 .

10. The compound of claim 1 , wherein R 4 is selected from H, halo, C 1-6 alkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, S(C 1-4 alkyl), and 6-membered heterocycloalkyl.

11. The compound of claim 1 , wherein R 4 is selected from halo, C 1-6 alkyl, C 1-4 alkoxy, C 1-4 haloalkoxy, S(C 1-4 alkyl), and 6-membered heterocycloalkyl.

12. The compound of claim 1 , wherein R 4 is selected from H, fluoro, chloro, methylthio, methoxy, methyl, trifluoromethoxy, and N-morpholino.

13. The compound of claim 1 , wherein W is CR 4 and R 4 is selected from H, halo, and S(C 1-6 alkyl).

14. The compound of claim 1 , wherein W is CR 4 and R 4 is selected from H, fluoro, and methylthio.

15. The compound of claim 1 , wherein R 5 is selected from H and fluoro.

16. The compound of claim 1 , wherein R 6 is selected from H, ethenyl, and C 1-6 hydroxyalkyl.

17. The compound of claim 1 , wherein R 6 is selected from H, ethenyl, and hydroxymethyl.

18. The compound of claim 1 , wherein R 7 is selected from H, and methyl.

19. The compound of claim 1 , wherein R 6 and R 7 form a ring of formula:

20. The compound of claim 1 , wherein R 6 and R 7 form a ring of formula:

wherein # indicates the ring carbon attached to the ring containing W.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: KANYO, ZOLTAN
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 050791/0648 →
CHANGE OF NAME Recorded Oct 22, 2019
From: RIB-X PHARMACEUTICALS, INC.
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 050785/0964 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: DUFFY, ERIN M
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 050790/0489 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: IPPOLITO, JOSEPH
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 050790/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2019
From: BHATTACHARJEE, ASHOKE
To: RIB-X PHARMACEUTICALS, INC.
Reel/Frame 050791/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2019
From: MELINTA THERAPEUTICS, INC.; MELINTA SUBSIDIARY CORP.
To: BIOVERSYS AG
Reel/Frame 050128/0253 →
RELEASE OF SECURITY INTEREST Recorded Apr 11, 2019
From: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
To: MELINTA THERAPEUTICS, INC.
Reel/Frame 048875/0750 →
SECURITY INTEREST Recorded Mar 19, 2019
From: MELINTA THERAPEUTICS, INC.; REMPEX PHARMACEUTICALS, INC.; CEMPRA PHARMACEUTICALS, INC.; MELINTA SUBSIDIARY CORP.
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS AGENT
Reel/Frame 048637/0784 →